Author Archives: Forest Ray, PhD

Amicus’ Gene Therapy for CLN6 Batten Given PRIME Status in Europe

The European Medicines Agency (EMA) has given priority medicines (PRIME) status to AT-GTX-501, Amicus Therapeutics‘ investigational gene therapy for CLN6 Batten disease, otherwise known as variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease. PRIME designation helps speed the development and regulatory review of promising medicines…